This document summarizes the key points from a seminar presentation on 21 CFR Part 822 Post Marketing Surveillance. It discusses how post-marketing surveillance helps monitor medical devices for side effects after market launch. It outlines the subparts that describe general provisions, notification requirements, post-market surveillance plan submission, FDA review process, manufacturer responsibilities, waivers and exemptions, record keeping and reporting. The presentation provides an overview of the regulatory requirements for conducting post-market surveillance of medical devices to identify unforeseen adverse events.